Pol theta enzyme identified as key driver of cancer resilience

Post author:admin
Post published:April 7, 2026
Post category:uncategorized

A cancer drug target already being investigated in clinical trials turns out to be doing something even more consequential than researchers realized.

Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.

Helpful Links

Subscribe To Us

By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy

UPCOMING EVENTS

You Might Also Like

Clonal hematopoiesis linked to increased heart disease risk in cancer patients receiving treatment

Bio-Rad launches vericheck ddPCR replication competent lentivirus and replication competent AAV kits for cell and gene therapy production

AIHW data reveals increase in waiting times for patients undergoing elective surgery in Australia’s public hospitals

Helpful Links

Subscribe To Us